Gianluigi Giannelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4856834/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Liver frailty and all-cause mortality in the older participants of the Salus in Apulia Study. GeroScience, 2022, 44, 835-845.	2.1	12
2	Role of plant-based diet in late-life cognitive decline: results from the Salus in Apulia Study. Nutritional Neuroscience, 2022, 25, 1300-1309.	1.5	15
3	Processed meat consumption and the risk of incident late-onset depression: a 12-year follow-up of the Salus in Apulia Study. Age and Ageing, 2022, 51, .	0.7	5
4	CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. Journal of Experimental and Clinical Cancer Research, 2022, 41, 65.	3.5	7
5	Exosomal FZD-7 Expression Is Modulated by Different Lifestyle Interventions in Patients with NAFLD. Nutrients, 2022, 14, 1133.	1.7	8
6	Effects of Grape Pomace Polyphenols and In Vitro Gastrointestinal Digestion on Antimicrobial Activity: Recovery of Bioactive Compounds. Antioxidants, 2022, 11, 567.	2.2	29
7	Variations in Circulating Levels of Angiopoietin-2 Over Time Are Predictive of Ramucirumab–Paclitaxel Therapy Outcome in Advanced Gastric Cancer: Results of Prospective Study. Frontiers in Oncology, 2022, 12, 862116.	1.3	2
8	Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma. Cancers, 2022, 14, 1902.	1.7	11
9	miR-195-5p Regulates Tight Junctions Expression via Claudin-2 Downregulation in Ulcerative Colitis. Biomedicines, 2022, 10, 919.	1.4	8
10	The Tumor Microenvironment Drives Intrahepatic Cholangiocarcinoma Progression. International Journal of Molecular Sciences, 2022, 23, 4187.	1.8	4
11	Validation and Ecological Niche Investigation of a New Fungal Intraspecific Competitor as a Biocontrol Agent for the Sustainable Containment of Aflatoxins on Maize Fields. Journal of Fungi (Basel, Switzerland), 2022, 8, 425.	1.5	2
12	The Increase of miR-195-5p Reduces Intestinal Permeability in Ulcerative Colitis, Modulating Tight Junctions' Expression. International Journal of Molecular Sciences, 2022, 23, 5840.	1.8	15
13	Retinal Vascular Density on Optical Coherence Tomography Angiography and Age-Related Central and Peripheral Hearing Loss in a Southern Italian Older Population. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 2169-2177.	1.7	6
14	Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy for Remission of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 922-933.	1.8	31
15	Late-onset depression is associated to age-related central auditory processing disorder in an older population in Southern Italy. GeroScience, 2021, 43, 1003-1014.	2.1	6
16	Heavy metals modulate <scp>DNA</scp> compaction and methylation at <scp>CpG</scp> sites in the metal hyperaccumulator <i>Arabidopsis halleri</i> . Environmental and Molecular Mutagenesis, 2021, 62, 133-142.	0.9	15
17	How gait influences frailty models and healthâ€related outcomes in clinicalâ€based and populationâ€based studies: a systematic review. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 274-297.	2.9	52
18	Physical Frailty, Multimorbidity, and All-Cause Mortality in an Older Population From Southern Italy: Results from the Salus in Apulia Study. Journal of the American Medical Directors Association, 2021, 22, 598-605.	1.2	53

#	Article	IF	CITATIONS
19	Phytoextraction efficiency of Pteris vittata grown on a naturally As-rich soil and characterization of As-resistant rhizosphere bacteria. Scientific Reports, 2021, 11, 6794.	1.6	20
20	Non Alcoholic Fatty Liver Disease Is Positively Associated with Increased Glycated Haemoglobin Levels in Subjects without Diabetes. Journal of Clinical Medicine, 2021, 10, 1695.	1.0	11
21	Performance of Fatty Liver Index in Identifying Non-Alcoholic Fatty Liver Disease in Population Studies. A Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1877.	1.0	37
22	Neurological diseases and COVID-19: prospective analyses using the UK Biobank. Acta Neurologica Belgica, 2021, 121, 1295-1303.	0.5	4
23	Prognostic significance of hypoxic and metabolic gene profiling in hepatocellular carcinoma. Liver Cancer International, 2021, 2, 15-26.	0.2	1
24	Epithelial–Mesenchymal Transition (EMT) Induced by TGF-β in Hepatocellular Carcinoma Cells Reprograms Lipid Metabolism. International Journal of Molecular Sciences, 2021, 22, 5543.	1.8	35
25	Dietary Habits and Nutrient Intakes Are Associated to Age-Related Central Auditory Processing Disorder in a Cohort From Southern Italy. Frontiers in Aging Neuroscience, 2021, 13, 629017.	1.7	4
26	Physical and cognitive profiles in motoric cognitive risk syndrome in an older population from Southern Italy. European Journal of Neurology, 2021, 28, 2565-2573.	1.7	23
27	Association Between Central and Peripheral Age-Related Hearing Loss and Different Frailty Phenotypes in an Older Population in Southern Italy. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 561.	1.2	31
28	Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis. American Journal of Gastroenterology, 2021, 116, 1833-1841.	0.2	15
29	Exosome Released FZD10 Increases Ki-67 Expression via Phospho-ERK1/2 in Colorectal and Gastric Cancer. Frontiers in Oncology, 2021, 11, 730093.	1.3	9
30	Associations between nutritional frailty and 8â€year allâ€cause mortality in older adults: The Salus in Apulia Study. Journal of Internal Medicine, 2021, 290, 1071-1082.	2.7	31
31	Traceability of Sicilian Durum Wheat Landraces and Historical Varieties by High Molecular Weight Glutenins Footprint. Agronomy, 2021, 11, 143.	1.3	10
32	Beverages Consumption and Oral Health in the Aging Population: A Systematic Review. Frontiers in Nutrition, 2021, 8, 762383.	1.6	21
33	Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10, 4638.	1.0	7
34	Comparing Soil vs. Foliar Nitrogen Supply of the Whole Fertilizer Dose in Common Wheat. Agronomy, 2021, 11, 2138.	1.3	12
35	Direct and Indirect Effect of TGFÎ ² on Treg Transendothelial Recruitment in HCC Tissue Microenvironment. International Journal of Molecular Sciences, 2021, 22, 11765.	1.8	7
36	Liver Fibrosis and 8-Year All-Cause Mortality Trajectories in the Aging Cohort of the Salus in Apulia Study. Biomedicines, 2021, 9, 1617.	1.4	2

#	Article	IF	CITATIONS
37	Relationship Among Adherence to the Mediterranean Diet and Anthropometric and Metabolic Parameters in Subjects with Obesity. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2021, 21, 1613-1619.	0.6	4
38	Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation. International Journal of Molecular Sciences, 2021, 22, 13090.	1.8	8
39	Impact of Different Operational Definitions of Sarcopenia on Prevalence in a Population-Based Sample: The Salus in Apulia Study. International Journal of Environmental Research and Public Health, 2021, 18, 12979.	1.2	6
40	A Gene-Based Machine Learning Classifier Associated to the Colorectal Adenoma—Carcinoma Sequence. Biomedicines, 2021, 9, 1937.	1.4	5
41	A family history of type 2 diabetes as a predictor of fatty liver disease in diabetes-free individuals with excessive body weight. Scientific Reports, 2021, 11, 24084.	1.6	9
42	Comparative analysis of 2 commercial molecular tests for the detection of gastroenteric viruses on stool samples. Diagnostic Microbiology and Infectious Disease, 2020, 96, 114893.	0.8	7
43	Effectiveness of a Controlled 5-FU Delivery Based on FZD10 Antibody-Conjugated Liposomes in Colorectal Cancer In vitro Models. Pharmaceutics, 2020, 12, 650.	2.0	21
44	Proteoglycan-4 is correlated with longer survival in HCC patients and enhances sorafenib and regorafenib effectiveness via CD44 in vitro. Cell Death and Disease, 2020, 11, 984.	2.7	14
45	Efficacy and safety of patient-led versus physician-led titration of basal insulin in patients with uncontrolled type 2 diabetes: a meta-analysis of randomized controlled trials. BMJ Open Diabetes Research and Care, 2020, 8, e001477.	1.2	7
46	Traditional Old Dietary Pattern of Castellana Grotte (Apulia) Is Associated with Healthy Outcomes. Nutrients, 2020, 12, 3097.	1.7	11
47	Higher Muscle Mass Implies Increased Free-Thyroxine to Free-Triiodothyronine Ratio in Subjects With Overweight and Obesity. Frontiers in Endocrinology, 2020, 11, 565065.	1.5	12
48	Sisters in structure but different in character, some benzaldehyde and cinnamaldehyde derivatives differentially tune Aspergillus flavus secondary metabolism. Scientific Reports, 2020, 10, 17686.	1.6	11
49	Adherence to a Mediterranean Diet and Thyroid Function in Obesity: A Cross-Sectional Apulian Survey. Nutrients, 2020, 12, 3173.	1.7	18
50	Activity Energy Expenditure Predicts Clinical Average Levels of Physical Activity in Older Population: Results from Salus in Apulia Study. Sensors, 2020, 20, 4585.	2.1	11
51	A Possible Role of FZD10 Delivering Exosomes Derived from Colon Cancers Cell Lines in Inducing Activation of Epithelial–Mesenchymal Transition in Normal Colon Epithelial Cell Line. International Journal of Molecular Sciences, 2020, 21, 6705.	1.8	15
52	Nutritional domains in frailty tools: Working towards an operational definition of nutritional frailty. Ageing Research Reviews, 2020, 64, 101148.	5.0	43
53	Impaired fasting plasma glucose is a risk indicator of interventricular septum thickening among non-diabetic subjects with obesity. Diabetes Research and Clinical Practice, 2020, 169, 108436.	1.1	6
54	The relationship between epigenetics and microbiota in neuropsychiatric diseases. Epigenomics, 2020, 12, 1559-1568.	1.0	11

#	Article	IF	CITATIONS
55	Adherence to a healthy lifestyle and multiple sclerosis: a case–control study from the UK Biobank. Nutritional Neuroscience, 2020, , 1-9.	1.5	4
56	Social Frailty in the COVID-19 Pandemic Era. Frontiers in Psychiatry, 2020, 11, 577113.	1.3	20
57	Generalizability of sodium-glucose co-transporter-2 inhibitors cardiovascular outcome trials to the type 2 diabetes population: a systematic review and meta-analysis. Cardiovascular Diabetology, 2020, 19, 87.	2.7	23
58	Seroprevalence of group B Coxsackieviruses: Retrospective study in an Italian population. Journal of Medical Virology, 2020, 92, 3138-3143.	2.5	9
59	Impaired Anti-Tumor T cell Response in Hepatocellular Carcinoma. Cancers, 2020, 12, 627.	1.7	22
60	Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib. PLoS ONE, 2020, 15, e0222259.	1.1	36
61	Association between adherence to the Mediterranean Diet and circulating Vitamin D levels. International Journal of Food Sciences and Nutrition, 2020, 71, 884-890.	1.3	30
62	Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell Death and Differentiation, 2020, 27, 2330-2343.	5.0	39
63	Relationship between Inflammatory Food Consumption and Age-Related Hearing Loss in a Prospective Observational Cohort: Results from the Salus in Apulia Study. Nutrients, 2020, 12, 426.	1.7	40
64	Exosomes for Diagnosis and Therapy in Gastrointestinal Cancers. International Journal of Molecular Sciences, 2020, 21, 367.	1.8	28
65	Traditional Dietary Patterns and Risk of Mortality in a Longitudinal Cohort of the Salus in Apulia Study. Nutrients, 2020, 12, 1070.	1.7	27
66	Ageâ€Related Central Auditory Processing Disorder, MCI, and Dementia in an Older Population of Southern Italy. Otolaryngology - Head and Neck Surgery, 2020, 163, 348-355.	1.1	39
67	Cross-sectional relationship among different anthropometric parameters and cardio-metabolic risk factors in a cohort of patients with overweight or obesity. PLoS ONE, 2020, 15, e0241841.	1.1	14
68	Higher Body Mass Index, Uric Acid Levels, and Lower Cholesterol Levels are Associated with Greater Weight Loss. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1268-1281.	0.6	3
69	Preliminary Trajectories in Dietary Behaviors during the COVID-19 Pandemic: A Public Health Call to Action to Face Obesity. International Journal of Environmental Research and Public Health, 2020, 17, 7073.	1.2	99
70	Hydroxyvitamin D Serum Levels are Negatively Associated with Platelet Number in a Cohort of Subjects Affected by Overweight and Obesity. Nutrients, 2020, 12, 474.	1.7	8
71	The Challenge of Antidepressant Therapeutics in Alzheimer's Disease. Advances in Experimental Medicine and Biology, 2020, 1260, 267-281.	0.8	4
72	Effects of a Low Carb Diet and Whey Proteins on Anthropometric, Hematochemical, and Cardiovascular Parameters in Subjects with Obesity. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2020, 20, 1719-1725.	0.6	7

#	Article	IF	CITATIONS
73	Title is missing!. , 2020, 15, e0241841.		0
74	Title is missing!. , 2020, 15, e0241841.		0
75	Title is missing!. , 2020, 15, e0241841.		0
76	Title is missing!. , 2020, 15, e0241841.		0
77	Title is missing!. , 2020, 15, e0241841.		0
78	Title is missing!. , 2020, 15, e0241841.		0
79	Frizzled-10 Extracellular Vesicles Plasma Concentration Is Associated with Tumoral Progression in Patients with Colorectal and Gastric Cancer. Journal of Oncology, 2019, 2019, 1-12.	0.6	24
80	FZD10 Carried by Exosomes Sustains Cancer Cell Proliferation. Cells, 2019, 8, 777.	1.8	31
81	Biopsychosocial frailty and the risk of incident dementia: The Italian longitudinal study on aging. Alzheimer's and Dementia, 2019, 15, 1019-1028.	0.4	47
82	Validation of Hepatocellular Carcinoma Experimental Models for TGF-β Promoting Tumor Progression. Cancers, 2019, 11, 1510.	1.7	21
83	The Interactivity between TGFβ and BMP Signaling in Organogenesis, Fibrosis, and Cancer. Cells, 2019, 8, 1130.	1.8	94
84	Down-Regulation of Cannabinoid Type 1 (CB1) Receptor and its Downstream Signaling Pathways in Metastatic Colorectal Cancer. Cancers, 2019, 11, 708.	1.7	17
85	Promising therapies for the treatment of frontotemporal dementia clinical phenotypes: from symptomatic to disease-modifying drugs. Expert Opinion on Pharmacotherapy, 2019, 20, 1091-1107.	0.9	15
86	Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistance. Liver International, 2019, 39, 43-62.	1.9	54
87	Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma. Liver International, 2019, 39, 1468-1477.	1.9	86
88	Uric Acid and Potassium Serum Levels Are Independent Predictors of Blood Pressure Non-Dipping in Overweight or Obese Subjects. Nutrients, 2019, 11, 2970.	1.7	9
89	TGF-Î ² as Multifaceted Orchestrator in HCC Progression: Signaling, EMT, Immune Microenvironment, and Novel Therapeutic Perspectives. Seminars in Liver Disease, 2019, 39, 053-069.	1.8	78
90	Sensorial frailty: age-related hearing loss and the risk of cognitive impairment and dementia in later life. Therapeutic Advances in Chronic Disease, 2019, 10, 204062231881100.	1.1	68

#	Article	IF	CITATIONS
91	Transforming Growth Factor-β Promotes Morphomechanical Effects Involved in Epithelial to Mesenchymal Transition in Living Hepatocellular Carcinoma. International Journal of Molecular Sciences, 2019, 20, 108.	1.8	10
92	Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 38-47.	1.8	42
93	Galunisertib suppresses the staminal phenotype in hepatocellular carcinoma by modulating CD44 expression. Cell Death and Disease, 2018, 9, 373.	2.7	31
94	Different Cognitive Frailty Models and Health- and Cognitive-related Outcomes in Older Age: From Epidemiology to Prevention. Journal of Alzheimer's Disease, 2018, 62, 993-1012.	1.2	214
95	Liver Angiopoietinâ€2 Is a Key Predictor of D e N ovo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Directâ€Acting Antivirals. Hepatology, 2018, 68, 1010-1024.	3.6	106
96	Aquaporin-9 Contributes to the Maturation Process and Inflammatory Cytokine Secretion of Murine Dendritic Cells. Frontiers in Immunology, 2018, 9, 2355.	2.2	17
97	BACE inhibitors in clinical development for the treatment of Alzheimer's disease. Expert Review of Neurotherapeutics, 2018, 18, 847-857.	1.4	66
98	Key Enabling Technologies for Point-of-Care Diagnostics. Sensors, 2018, 18, 3607.	2.1	61
99	PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget, 2018, 9, 8584-8596.	0.8	53
100	Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model. Archives of Toxicology, 2018, 92, 2297-2309.	1.9	26
101	Immune Cells and Microbiota Response to Iron Starvation. Frontiers in Medicine, 2018, 5, 109.	1.2	16
102	TGF-β and the Tissue Microenvironment: Relevance in Fibrosis and Cancer. International Journal of Molecular Sciences, 2018, 19, 1294.	1.8	231
103	Social Dysfunction in Older Age and Relationships with Cognition, Depression, and Apathy: The GreatAGE Study. Journal of Alzheimer's Disease, 2018, 65, 989-1000.	1.2	42
104	NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC. Cell Death and Disease, 2017, 8, e2634-e2634.	2.7	32
105	Transforming growth factor-Î ² -induced plasticity causes a migratory stemness phenotype in hepatocellular carcinoma. Cancer Letters, 2017, 392, 39-50.	3.2	69
106	Midlife Metabolic Profile and the Risk of Late-Life Cognitive Decline. Journal of Alzheimer's Disease, 2017, 59, 121-130.	1.2	41
107	Precision medicine for hepatocelluar carcinoma using molecular pattern diagnostics: results from a preclinical pilot study. Cell Death and Disease, 2017, 8, e2867-e2867.	2.7	8
108	Role of the Transforming Growth Factor-Î ² in regulating hepatocellular carcinoma oxidative metabolism. Scientific Reports, 2017, 7, 12486.	1.6	54

#	Article	IF	CITATIONS
109	Microenvironment inflammatory infiltrate drives growth speed and outcome of hepatocellular carcinoma: a prospective clinical study. Cell Death and Disease, 2017, 8, e3017-e3017.	2.7	45
110	Innovative biomarkers in psychiatric disorders: a major clinical challenge in psychiatry. Expert Review of Proteomics, 2017, 14, 809-824.	1.3	36
111	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. Journal of Hepatology, 2017, 67, 1194-1203.	1.8	77
112	The TGF-β pathway: a pharmacological target in hepatocellular carcinoma?. Hepatic Oncology, 2017, 4, 35-38.	4.2	2
113	Dietary ω-3 Polyunsaturated Fatty Acids Inhibit Tumor Growth in Transgenic ApcMin/+ Mice, Correlating with CB1 Receptor Up-Regulation. International Journal of Molecular Sciences, 2017, 18, 485.	1.8	23
114	Role of epithelial to mesenchymal transition in hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 798-808.	1.8	457
115	Laminin-332 sustains chemoresistance and quiescence as part of the human hepatic cancer stem cell niche. Journal of Hepatology, 2016, 64, 609-617.	1.8	102
116	Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the lamininâ€322∫1±3 integrin axis recovery of focal adhesion kinase ubiquitination. Hepatology, 2016, 64, 2103-2117.	3.6	80
117	Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut, 2016, 65, 861-869.	6.1	207
118	<scp>TGF</scp> â€ \hat{i}^2 signalling and liver disease. FEBS Journal, 2016, 283, 2219-2232.	2.2	457
119	The rationale for targeting <scp>TGF</scp> â€Î² in chronic liver diseases. European Journal of Clinical Investigation, 2016, 46, 349-361.	1.7	60
120	Lysophosphatidic Acid Receptor LPAR6 Supports the Tumorigenicity of Hepatocellular Carcinoma. Cancer Research, 2015, 75, 532-543.	0.4	49
121	A mesenchymalâ€like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. International Journal of Cancer, 2015, 136, E161-72.	2.3	108
122	Transforming Growth Factor-Î ² as a Therapeutic Target in Hepatocellular Carcinoma. Cancer Research, 2014, 74, 1890-1894.	0.4	233
123	Interplay between cancer cells, macrophages and natural killer cells may actually decide the outcome of therapy with sorafenib. Hepatology, 2014, 60, 430-430.	3.6	2
124	Moving towards personalised therapy in patients with hepatocellular carcinoma: the role of the microenvironment. Gut, 2014, 63, 1668-1676.	6.1	94
125	Circulating TGF- $\hat{1}^2$ 1-related biomarkers in patients with hepatocellular carcinoma and their association with HCC staging scores. Cancer Letters, 2014, 353, 264-271.	3.2	21
126	A phase 2 study of a novel transforming growth factor-beta (TGF-β1) receptor I kinase inhibitor, LY2157299 monohydrate (LY), in patients with advanced hepatocellular carcinoma (HCC) Journal of Clinical Oncology, 2014, 32, LBA173-LBA173.	0.8	33

#	Article	IF	CITATIONS
127	Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma. World Journal of Gastroenterology, 2014, 20, 4128.	1.4	34
128	Reply. Hepatology, 2013, 57, 418-419.	3.6	1
129	Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature. Molecular BioSystems, 2013, 9, 1127-1138.	2.9	29
130	Differential Inhibition of the TGF-Î ² Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-Î ² Receptor Type II. PLoS ONE, 2013, 8, e67109.	1.1	86
131	TGF-Beta Inihibitor-loaded Polyelectrolyte Multilayers Capsules for Sustained Targeting of Hepatocarcinoma Cells. Current Pharmaceutical Design, 2012, 18, 4155-4164.	0.9	16
132	Editorial: [Hot Topic: TGF-β1 in Pre-Malignant and Malignant Liver Disease]. Current Pharmaceutical Design, 2012, 18, 4071-4071.	0.9	1
133	The TGF-β Signaling Pathway as a Pharmacological Target in a Hepatocellular Carcinoma. Current Pharmaceutical Design, 2012, 18, 4148-4154.	0.9	16
134	SCCAâ€IC serum levels are predictive of clinical response in HCV chronic hepatitis to antiviral therapy: a multicentric prospective study. Journal of Viral Hepatitis, 2012, 19, 704-710.	1.0	11
135	Polyelectrolyte Capsules as Carriers for Growth Factor Inhibitor Delivery to Hepatocellular Carcinoma. Macromolecular Bioscience, 2012, 12, 656-665.	2.1	24
136	PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. International Journal of Cancer, 2012, 130, 2505-2513.	2.3	36
137	Body Mass Index and Serum Proteomic Profile in Breast Cancer and Healthy Women: A Prospective Study. PLoS ONE, 2012, 7, e49631.	1.1	14
138	Automatic transwell assay by an EIS cell chip to monitor cell migration. Lab on A Chip, 2011, 11, 4081.	3.1	45
139	Hepatic stellate cells stimulate HCC cell migration via laminin-5 production. Clinical Science, 2011, 121, 159-168.	1.8	73
140	Inhibiting TGF-β signaling in hepatocellular carcinoma. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 214-223.	3.3	60
141	Drug-loaded polyelectrolyte microcapsules for sustained targeting of cancer cells. Advanced Drug Delivery Reviews, 2011, 63, 847-864.	6.6	182
142	Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study. Cancer Chemotherapy and Pharmacology, 2011, 68, 79-86.	1.1	42
143	Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology, 2011, 54, 920-930.	3.6	122
144	Quantitative Determination of Hepatitis C Core Antigen in Therapy Monitoring for Chronic Hepatitis C. Intervirology, 2011, 54, 61-65.	1.2	22

#	Article	IF	CITATIONS
145	PI3K Functions in Cancer Progression, Anticancer Immunity and Immune Evasion by Tumors. Clinical and Developmental Immunology, 2011, 2011, 1-10.	3.3	62
146	Involvement of ADAMs in tumorigenesis and progression of hepatocellular carcinoma: Is it merely fortuitous or a real pathogenic link?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 74-81.	3.3	10
147	Down-regulation of connective tissue growth factor by inhibition of transforming growth factor β blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology, 2010, 51, 523-534.	3.6	158
148	Targeting transforming growth factor (TGF)-βRI inhibits activation of β1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology, 2009, 49, 839-850.	3.6	127
149	Inhibition of transforming growth factor β receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology, 2009, 50, 1140-1151.	3.6	111
150	The epithelial-mesenchymal transition: Fact or fiction in cancer?. Hepatology, 2009, 50, 1344-1346.	3.6	8
151	Reply:. Hepatology, 2009, 50, 2051-2051.	3.6	0
152	Immune complexed (IC) hepatitis C virus (HCV) in chronically and acutely HCV-infected patients. Medical Microbiology and Immunology, 2009, 198, 13-18.	2.6	5
153	Tissue expression of Squamous Cellular Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Molecular Cancer, 2009, 8, 29.	7.9	28
154	HCC heterogeneity: molecular pathogenesis and clinical implications. Cellular Oncology, 2009, 31, 227-33.	1.9	24
155	Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology, 2008, 47, 1557-1566.	3.6	227
156	The use of different Peg-interferon α-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. Journal of Viral Hepatitis, 2008, 15, 300-304.	1.0	5
157	AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 2008, 8, 200.	1.1	109
158	EGFR and VEGFR as potential target for biological therapies in HCC cells. Cancer Letters, 2008, 262, 257-264.	3.2	48
159	Basiliximab Versus Steroids in Double Therapy Immunosuppression in Liver Transplantation: A Prospective Randomized Clinical Trial. Transplantation, 2008, 86, 925-931.	0.5	45
160	Editorial [Hot Topic:Resent and Future Therapies for the Hepatocellular Carcinoma (Executive Editor:) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf

161	Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma. Current Pharmaceutical Design, 2007, 13, 3301-3304.	0.9	11
162	Rationale for New Drugs Targeting the Tissue Microenvironment in Patients with HCC. Current Pharmaceutical Design, 2007, 13, 3288-3291.	0.9	8

#	Article	IF	CITATIONS
163	Clinical validation of combined serological biomarkers for improved hepatocellular carcinoma diagnosis in 961 patients. Clinica Chimica Acta, 2007, 383, 147-152.	0.5	89
164	Laminin-5 stimulates hepatocellular carcinoma growth through a different function of α6β4 and α3β1 integrins. Hepatology, 2007, 46, 1801-1809.	3.6	63
165	Endometriosis is characterized by an impaired localization of laminin-5 and α3β1 integrin receptor. International Journal of Gynecological Cancer, 2007, 17, 242-247.	1.2	16
166	Single hepatocellular carcinoma ranging from 3 to 5cm: radiofrequency ablation or resection?. Hpb, 2007, 9, 429-434.	0.1	84
167	New frontiers in biomarkers for hepatocellular carcinoma. Digestive and Liver Disease, 2006, 38, 854-859.	0.4	34
168	Tace treatment outcome: (almost) everything is predictable. Digestive and Liver Disease, 2006, 38, 940-941.	0.4	1
169	Novel Concepts in Hepatocellular Carcinoma: From Molecular Research to Clinical Practice. Journal of Clinical Gastroenterology, 2006, 40, 842-846.	1.1	29
170	Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. European Journal of Clinical Investigation, 2006, 36, 73-77.	1.7	10
171	ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. Biochemical Pharmacology, 2006, 71, 479-485.	2.0	36
172	Antifibrogenic Effect of IFN-α2b on Hepatic Stellate Cell Activation by Human Hepatocytes. Journal of Interferon and Cytokine Research, 2006, 26, 301-308.	0.5	19
173	Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. International Journal of Cancer, 2005, 116, 579-583.	2.3	56
174	MMP and TIMP assay in cancer: Biological and clinical significance. International Journal of Cancer, 2005, 116, 1002-1003.	2.3	7
175	SCCA antigen combined with alpha-fetoprotein as serologic markers of HCC. International Journal of Cancer, 2005, 117, 506-509.	2.3	58
176	The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Current Medical Research and Opinion, 2005, 21, 327-332.	0.9	43
177	Expression of α6β4 and α3β1 Integrins in Bullous Pemphigoid and Pemphigus Vulgaris. Letters in Drug Design and Discovery, 2005, 2, 228-231.	0.4	О
178	Laminin-5 With Transforming Growth Factor-β1 Induces Epithelial to Mesenchymal Transition in Hepatocellular Carcinoma. Gastroenterology, 2005, 129, 1375-1383.	0.6	247
179	Clinical Role of Serum and Tissue Matrix Metalloprotease-9 Expression in Chronic HCV Patients Treated with Pegylated IFN-α2b and Ribavirin. Journal of Interferon and Cytokine Research, 2005, 25, 453-458.	0.5	7
180	Laminin-5 offsets the efficacy of gefitinib (â€~Iressa') in hepatocellular carcinoma cells. British Journal of Cancer, 2004, 91, 1964-1969.	2.9	50

#	Article	IF	CITATIONS
181	Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. International Journal of Cancer, 2004, 109, 782-785.	2.3	31
182	Case of multiple myeloma mimicking an infectious disease with fever, intrahepatic cholestasis, renal failure, and pulmonary insufficiency. American Journal of Hematology, 2003, 72, 38-42.	2.0	12
183	Cancer Invasion: Watch Your Neighbourhood!. Tumori, 2003, 89, 343-348.	0.6	28
184	Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clinical Cancer Research, 2003, 9, 3684-91.	3.2	68
185	Proteolytic Balance in Patients with Multiple Sclerosis During Interferon Treatment. Journal of Interferon and Cytokine Research, 2002, 22, 689-692.	0.5	6
186	Transforming Growth Factor-β1 Triggers Hepatocellular Carcinoma Invasiveness via α3β1 Integrin. American Journal of Pathology, 2002, 161, 183-193.	1.9	159
187	Gelatinase Levels in Male and Female Breast Cancer. Biochemical and Biophysical Research Communications, 2002, 292, 161-166.	1.0	25
188	Clinical role of MMP-2/TIMP-2 imbalance in hepatocellular carcinoma. International Journal of Cancer, 2002, 97, 425-431.	2.3	174
189	Rat Hindlimb Unloading by Tail Suspension Reduces Osteoblast Differentiation, Induces IL-6 Secretion, and Increases Bone Resorption in Ex Vivo Cultures. Calcified Tissue International, 2002, 70, 176-185.	1.5	54
190	Gelatinase expression at positive patch test reactions. Contact Dermatitis, 2002, 46, 280-285.	0.8	17
191	Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatology Research, 2002, 24, 50-59.	1.8	35
192	Malignant fibrous histiocytoma arising on chronic osteomyelitis. Journal of the European Academy of Dermatology and Venereology, 2002, 16, 390-392.	1.3	5
193	Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clinical and Experimental Metastasis, 2002, 19, 217-223.	1.7	70
194	Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. Journal of Cell Science, 2002, 115, 2919-2929.	1.2	63
195	Human Hepatocellular Carcinoma (HCC) Cells Require Both α3β1 Integrin and Matrix Metalloproteinases Activity for Migration and Invasion. Laboratory Investigation, 2001, 81, 613-627.	1.7	134
196	Characterization of Morphological and Cytoskeletal Changes in MCF10A Breast Epithelial Cells Plated on Laminin-5: Comparison with Breast Cancer Cell Line MCF7. Cell Communication and Adhesion, 2001, 8, 29-44.	1.0	12
197	Biological and clinical relevance of Laminin-5 in cancer. , 2000, 18, 439-443.		100
198	Role of Cell Surface Metalloprotease Mt1-Mmp in Epithelial Cell Migration over Laminin-5. Journal of Cell Biology, 2000, 148, 615-624.	2.3	596

#	Article	IF	CITATIONS
199	A Pilot Study of Daily Subcutaneous Interleukin-10 in Patients with Chronic Hepatitis C Infection. Journal of Interferon and Cytokine Research, 1999, 19, 1265-1270.	0.5	28
200	Expression of Matrix Metalloprotease-2-Cleaved Laminin-5 in Breast Remodeling Stimulated by Sex Steroids. American Journal of Pathology, 1999, 154, 1193-1201.	1.9	71
201	Induction of Cell Migration by Matrix Metalloprotease-2 Cleavage of Laminin-5. Science, 1997, 277, 225-228.	6.0	1,120
202	Fate of antibody to interferon (IFN) in chronic hepatitis C patients treated with recombinant IFN alpha 2 and retreated with lymphoblastoid IFN alpha. International Hepatology Communications, 1995, 4, 232-237.	0.7	7
203	Psoriatic lesions in patients with chronic liver disease are distinct from psoriasis vulgaris lesions, as judged on basis of integrin adhesion receptors. Hepatology, 1994, 20, 56-65.	3.6	37
204	Psoriatic lesions in patients with chronic liver disease are distinct from psoriasis vulgaris lesions, as judged on basis of integrin adhesion receptors. Hepatology, 1994, 20, 56-65.	3.6	11
205	Occurrence of Hepatitis Delta Virus Infection in Hepatitis B Virus-Infected Patients with Different Serum Patterns of PreS Gene-Encoded Proteins. Digestion, 1993, 54, 9-14.	1.2	11
206	Hepatitis C Virus Infection in Anti-HBe-Positive HBsAg Carriers with Chronic Liver Disease. Digestion, 1991, 50, 121-126.	1.2	3